Zollinger‑Ellison Syndrome (Type I) – A Patient‑Friendly Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to produce large amounts of gastric acid, leading to severe peptic ulcers and other gastrointestinal problems.

Type I ZES refers specifically to the form most commonly associated with multiple endocrine neoplasia type 1 (MEN‑1). In MEN‑1, patients inherit a mutation in the MEN1 tumor‑suppressor gene, predisposing them to tumors of the parathyroid, pituitary, and pancreas (including gastrinomas).

• Who it affects: Adults aged 30–60, with a slight male predominance (≈55 % male). In type I, up to 30 % of MEN‑1 patients develop gastrinomas, but only about 2–5 % of all ZES cases are type I.
• Prevalence: Overall ZES occurs in roughly 1–3 per million people worldwide. Type I accounts for ~10 % of those cases.

Because the condition is so uncommon, many patients experience delayed diagnosis—often several years after symptoms begin.

Symptoms

Symptoms arise from chronic hyper‑acid secretion and from the tumor itself. They can be intermittent at first and may mimic more common conditions such as gastro‑oesophageal reflux disease (GERD) or peptic ulcer disease.

Gastro‑intestinal symptoms

• Abdominal pain: Crampy, often epigastric, worsening after meals.
• Diarrhea: 3–6 watery stools per day; can be chronic or episodic.
• Steatorrhea (fatty stools): Due to acid‑inactivated pancreatic enzymes.
• Nausea & vomiting: May accompany ulcer perforation.
• Refractory or recurrent peptic ulcers: Ulcers that do not heal with standard therapy, often located in atypical sites (duodenum distal to the bulb, jejunum).
• Gastro‑oesophageal reflux (GERD): Frequently severe and resistant to proton‑pump inhibitors (PPIs) alone.

Systemic symptoms

• Weight loss: From malabsorption and chronic diarrhea.
• Fatigue & weakness: Resulting from anemia or electrolyte imbalance.
• Dehydration: Due to fluid loss from diarrhea.

Signs related to MEN‑1 (type I specific)

• Hyperparathyroidism: Elevated calcium, kidney stones.
• Pituitary tumors: Headaches, visual field defects, hormonal disturbances.

Causes and Risk Factors

ZES is a neuroendocrine tumor syndrome. Understanding the underlying cause helps identify at‑risk individuals.

Primary cause

• Gastrinoma: A neuroendocrine tumor that secretes gastrin. In type I, these tumors are usually small, multiple, and located in the duodenum or pancreas.
• MEN‑1 gene mutation: Autosomal‑dominant inheritance of a loss‑of‑function mutation in the MEN1 tumor suppressor gene (chromosome 11q13). Over 90 % of MEN‑1 families carry this mutation.

Risk factors

• Family history of MEN‑1 or known MEN1 mutation.
• Previous diagnosis of other MEN‑1 related tumors (parathyroid, pituitary).
• Chronic atrophic gastritis or pernicious anemia (these are risk factors for sporadic ZES, not type I, but worth noting).

Diagnosis

Because symptoms overlap with far more common conditions, a systematic approach is essential.

1. Clinical suspicion

Recurrent, treatment‑resistant ulcers, especially distal duodenal ulcers, plus secretory diarrhea should prompt further work‑up.

2. Laboratory testing

• Fasting serum gastrin level: Levels >1000 pg/mL (10‑fold the upper limit) in the presence of gastric acid hypersecretion are highly suggestive. (Mayo Clinic, 2023)
• Secretin stimulation test: Paradoxical rise in gastrin after IV secretin (>120 pg/mL increase) is the gold standard for gastrinoma detection.
• Calcium level & PTH: Screen for hyperparathyroidism (MEN‑1 component).
• Chromogranin A: Elevated in many neuroendocrine tumors, though not specific.

3. Imaging studies

• Endoscopic ultrasound (EUS): Sensitive for small (<1 cm) duodenal gastrinomas.
• Multiphasic contrast‑enhanced CT or MRI: Detects larger lesions and metastatic disease.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Highly sensitive for neuroendocrine tumor localization.

4. Endoscopy

Upper gastrointestinal endoscopy documents the number, size, and location of ulcers and may reveal the tumor directly if it protrudes into the lumen.

5. Genetic testing

When MEN‑1 is suspected, genetic testing for MEN1 mutations is recommended for the patient and first‑degree relatives.

Treatment Options

Management aims to (1) control gastric acid hypersecretion, (2) remove or control the gastrinoma(s), and (3) address MEN‑1 related tumors.

Acid‑suppression therapy

• High‑dose proton pump inhibitors (PPIs): Omeprazole 40–80 mg daily or equivalent; may be required lifelong. PPIs normalize gastric pH, heal ulcers, and reduce diarrhea.
• Histamine‑2 receptor antagonists (H2RAs): Less effective as monotherapy but can be used adjunctively.

Surgical options

• Localized duodenal gastrinomas: Enucleation or limited duodenotomy with tumor excision. Success rates >80 % for cure when disease is confined.
• Pancreatic gastrinomas: Pancreaticoduodenectomy (Whipple) or distal pancreatectomy for larger lesions.
• Metastatic disease: Cytoreductive liver surgery or liver-directed therapies (radiofrequency ablation, embolization).

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin release and may shrink tumors.
• Targeted therapy (everolimus, sunitinib): Approved for advanced pancreatic neuroendocrine tumors; modest tumor control.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE: Effective for somatostatin‑receptor positive disease, improving progression‑free survival.

Management of MEN‑1 components

• Parathyroidectomy for hyperparathyroidism.
• Transsphenoidal surgery or medical control (dopamine agonists, somatostatin analogues) for pituitary adenomas.

Lifestyle and supportive measures

• Low‑fat, low‑fiber diet initially to lessen diarrhea.
• Small, frequent meals; avoid large meals that provoke acid release.
• Hydration & oral rehydration solutions to replace lost electrolytes.
• Calcium and vitamin D supplementation if hyperparathyroidism is present.

Living with Zollinger‑Ellison Syndrome (Type I)

Long‑term management is a partnership between you, gastroenterologists, endocrinologists, and surgeons.

Medication adherence

• Take PPIs exactly as prescribed; never skip doses.
• Keep a medication diary; set phone reminders.

Monitoring

• Annual serum gastrin level and fasting gastric pH (if symptoms change).
• Regular imaging (EUS or MRI) every 1–2 years to detect new gastrinomas.
• Screen for MEN‑1 manifestations annually (calcium, PTH, pituitary hormone panels).

Dietary tips

• Prefer lean proteins, cooked vegetables, and low‑acid fruits (bananas, melons).
• Avoid caffeine, alcohol, spicy foods, and citrus which can exacerbate acid output.
• Limit NSAIDs and aspirin unless advised by a physician, as they increase ulcer risk.

Psychosocial support

• Join support groups for rare endocrine tumors (e.g., NET Patient Foundation).
• Consider counseling to manage chronic disease anxiety.

Family planning

If you carry a MEN‑1 mutation, genetic counseling is recommended before conceiving. Prenatal testing or pre‑implantation genetic diagnosis (PGD) are options for families desiring to avoid transmission.

Prevention

Because type I ZES is genetically driven, primary prevention is limited. However, you can reduce disease burden:

• Genetic counseling: Identify at‑risk relatives early.
• Regular screening: Early detection of gastrinomas and MEN‑1 related tumors improves outcomes.
• Avoid known ulcer‑aggravating agents: NSAIDs, smoking, excessive alcohol.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems.

• Perforated ulcer: Emergency surgery required; mortality 5–10 %.
• Gastrointestinal bleeding: Can be massive; may need endoscopic or surgical intervention.
• Obstruction: From ulcer scarring or tumor growth.
• Metastatic disease: Liver is the most common site; reduces survival.
• Nutritional deficiencies: Iron, vitamin B12, and fat‑soluble vitamins due to malabsorption.
• Osteoporosis: Chronic hyperparathyroidism and malabsorption of calcium.

When to Seek Emergency Care

---

References (selected):

• Mayo Clinic. Zollinger‑Ellison Syndrome. Updated 2023. https://www.mayoclinic.org/...
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2022.
• Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome)”. 2024.
• World Health Organization. Classification of Neuroendocrine Tumors. 2021.
• Jenkins et al. “Management of MEN‑1 associated gastrinomas.” Journal of Clinical Endocrinology & Metabolism, 2022;107(9):3075‑3085.
• Strosberg et al. “Peptide receptor radionuclide therapy for gastro‑enteropancreatic neuroendocrine tumors.” NEJM, 2023;388:1133‑1144.